Anti-NMDA receptor encephalitis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
Encephalitis has an annual incidence of 2-3 per 100,000, with 40% being infectious, 40% of unknown cause, and 20% immune-mediated. Anti-NMDA receptor encephalitis and VGK Complex antibody-positive encephalitis are major immune-mediated categories. It is more common in women and younger patients.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
Line 10: Line 11:


*While 40% of cases are infectious and 40% are attributable to unknown causes, at least 20% are immune-mediated, with anti-NMDA-receptor encephalitis (4%) and VGK Complex antibody-positive encephalitis (3%) constituting the major categories.
*While 40% of cases are infectious and 40% are attributable to unknown causes, at least 20% are immune-mediated, with anti-NMDA-receptor encephalitis (4%) and VGK Complex antibody-positive encephalitis (3%) constituting the major categories.
*The condition is more prevalent among women (81%) and younger patients (37% 18 years, 95% 45 years); however, in the age categories younger than 12 years and older than 45 years, the disease is more prevalent among men nearly half of patients are male.


==References==
==References==
Line 16: Line 19:
[[Category:Rheumatology]]
[[Category:Rheumatology]]
[[Category:Disease]]
[[Category:Disease]]
 
<ref name="pmid21331529">{{cite journal| author=Irani SR, Vincent A| title=NMDA receptor antibody encephalitis. | journal=Curr Neurol Neurosci Rep | year= 2011 | volume= 11 | issue= 3 | pages= 298-304 | pmid=21331529 | doi=10.1007/s11910-011-0186-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21331529  }} </ref>
<ref name="pmid25340058">{{cite journal| author=Hacohen Y, Absoud M, Hemingway C, Jacobson L, Lin JP, Pike M | display-authors=etal| title=NMDA receptor antibodies associated with distinct white matter syndromes. | journal=Neurol Neuroimmunol Neuroinflamm | year= 2014 | volume= 1 | issue= 1 | pages= e2 | pmid=25340058 | doi=10.1212/NXI.0000000000000002 | pmc=4202680 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25340058  }} </ref>
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 08:18, 13 May 2023

Anti-NMDA receptor encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anti-NMDA receptor encephalitis from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anti-NMDA receptor encephalitis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anti-NMDA receptor encephalitis epidemiology and demographics

CDC on Anti-NMDA receptor encephalitis epidemiology and demographics

Anti-NMDA receptor encephalitis epidemiology and demographics in the news

Blogs on Anti-NMDA receptor encephalitis epidemiology and demographics

Directions to Hospitals Treating Anti-NMDA receptor encephalitis

Risk calculators and risk factors for Anti-NMDA receptor encephalitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; AE Dheeraj Makkar, M.D.[2]

Overview

Encephalitis has an annual incidence of 2-3 per 100,000, with 40% being infectious, 40% of unknown cause, and 20% immune-mediated. Anti-NMDA receptor encephalitis and VGK Complex antibody-positive encephalitis are major immune-mediated categories. It is more common in women and younger patients.

Epidemiology and Demographics

Encephalitis due to any cause has a yearly incidence of 2–3 per 100,000 in northern Europe, which is half the incidence of multiple sclerosis (4–8 per 100,000 annually).

  • While 40% of cases are infectious and 40% are attributable to unknown causes, at least 20% are immune-mediated, with anti-NMDA-receptor encephalitis (4%) and VGK Complex antibody-positive encephalitis (3%) constituting the major categories.
  • The condition is more prevalent among women (81%) and younger patients (37% 18 years, 95% 45 years); however, in the age categories younger than 12 years and older than 45 years, the disease is more prevalent among men nearly half of patients are male.

References

[1] [2] Template:WH Template:WS

  1. Irani SR, Vincent A (2011). "NMDA receptor antibody encephalitis". Curr Neurol Neurosci Rep. 11 (3): 298–304. doi:10.1007/s11910-011-0186-y. PMID 21331529.
  2. Hacohen Y, Absoud M, Hemingway C, Jacobson L, Lin JP, Pike M; et al. (2014). "NMDA receptor antibodies associated with distinct white matter syndromes". Neurol Neuroimmunol Neuroinflamm. 1 (1): e2. doi:10.1212/NXI.0000000000000002. PMC 4202680. PMID 25340058.